Clinical Trial

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Study acronym: frontMIND
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2021-03-26; most recent amendment 2026-03-27.
Status change: Recruiting → Active, Not Recruiting 2023-04-04
Status change: Not Yet Recruiting → Recruiting 2021-05-25
Trial Details
NCT Number NCT04824092
Lead Sponsor Incyte Corporation
Conditions Diffuse Large B-cell Lymphoma
Enrollment 899 participants
Start Date 2021-05-11
Primary Completion 2026-09-01 (estimated)
Study Completion 2027-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-01